Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
Browsing: Taxonomy > Drug development
A new drug, termed ixazomib, is to be used in combination with standard treatments and has been made available on the Cancer Drug Fund.
To mark World Cancer Day we are highlighting the most significant advancements in modern oncology to investigate how the field has advanced and what hurdles still need to be overcome.
From clinical trial results to major drug approvals, here we present an overview of the latest industry news from the biggest players in oncology.
Merck has extended its all-important lung-cancer lead, after combination Phase III trial demonstrates that Keytruda extends lung cancer survival.
In this article from Future Oncology, the author considers the data supporting the sequential use of available EGFR TKIs and key considerations for selection of first-line treatment.
The FDA has expanded the label for AstraZeneca’s oral PARP inhibitor olaparib to include the treatment of patients with metastatic breast cancer whose disease is associated with a BRCA gene mutation.
In this review piece, we take a look at the most read cancer news stories from over the past year; highlights include drug approvals, genetic discoveries and immunotherapy advancements.
Researchers from the Case Western Reserve University (OH, USA) have demonstrated how a computer program can suggest novel cancer treatments.